Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board of Directors

 Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board  of Directors  WOODBRIDGE, ON, March 10, 2014 /CNW/ - Pivotal Therapeutics Inc. (OTCQX:  PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3  therapies for cardiovascular disease (CVD) and overall health, announced today  that James Connolly has been appointed to the Company's Board of Directors,  effective immediately. Mr. Connolly brings over 27 years of experience in the  pharmaceutical industry to Pivotal, including 23 years in various leadership  positions at Wyeth, formerly American Home Products, a $23 billion  pharmaceutical and health products company that was acquired by Pfizer in 2009.  During his 23 years at Wyeth, Jim served in a series of leadership roles of  increasing responsibility including Executive Vice President and General  Manager, Wyeth Vaccines, President, Wyeth Canada, Vice President - Sales and  Marketing, Area Business Director, Business Director - Wyeth/Medco joint  venture and Finance Director. Under Mr. Connolly's stewardship from 2005-2009,  Wyeth's vaccines business grew from $800 million to over $3 billion driven  principally with the creation of the first true commercial blockbuster  vaccine, Prevnar. During Jim's tenure leading Wyeth Canada, sales more than  doubled to over $650 million in less than four years, and all key promoted  brands including Effexor XR, Prevnar, Enbrel, Alesse, Premarin and BeneFix  achieved the #1 market share position in each of their respective categories.  "We are very pleased to welcome Jim to the Board of Directors of Pivotal  Therapeutics," said Dr. George Jackowski, Co-founder and Chairman of Pivotal's  Board of Directors. "Jim's wealth of experience in brand establishment,  commercialization and growing sales will be invaluable as the Company expands  its commercialization team to execute the broader launch of its Medical Food  VASCAZEN(®).( )  "I am excited to be joining Pivotal's board of directors and working with the  company to help strengthen the overall commercialization efforts," stated Mr.  Connolly. "Treating an Omega-3 deficiency with an innovative Medical Food such  as VASCAZEN(®) is a unique approach to this large market and represents a  significant opportunity."  Mr. Connolly currently serves as an advisor at Crossover Healthcare Fund,  director of Vaxess Technologies and a director at Aeras, a non-profit biotech  organization developing vaccines for tuberculosis and other neglected  diseases, where he formerly served as CEO until 2013. He holds a B.S. in  Business Administration from Washington University, St. Louis, MO.  About Pivotal Therapeutics Inc.  Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CSE: PVO) specialty  pharmaceutical company with a focus on cardiovascular disease and overall  health. Pivotal Therapeutics' lead product VASCAZEN(®) is a prescription only  Medical Food formulated to meet the dietary Omega-3 deficient needs of  patients with cardiovascular disease through elevating Eicosapentaenoic acid  (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of  cardiovascular complications. OMAZEN(® )is a pharmaceutical grade Omega-3  providing over 90% pure Omega-3 in each capsule for the maintenance of good  health. OMAZEN(®) is a patented product available for sale and distribution  in Canada.  About VASCAZEN(®)  VASCAZEN(®) is currently available in the U.S. as a prescription only Medical  Food specifically formulated for the dietary management of an Omega-3  deficiency in cardiovascular patients. VASCAZEN(®) is a >90% pure Omega-3  with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series  of both U.S. and foreign patents. VASCAZEN(®) has been clinically shown to  correct an Omega-3 deficiency within eight weeks of treatment with positive  concomitant effects on the lipid profiles, mainly a 48% reduction of  triglycerides and an increase of HDL without negative impact on the LDL-C  lipid profile.  VASCAZEN(®)'s results were achieved with a dose of 3 grams of  EPA and DHA per day of a prescription grade, high purity Omega-3.  Disclosure Notice The information contained in this document is as of March 10, 2014. This press  release contains forward-looking statements. Such forward-looking statements  are subject to a number of risks, assumptions and uncertainties that could  cause Pivotal's actual results to differ materially from those projected in  such forward-looking statements. These statements can be identified by the use  of words such as "will", "anticipate", "estimate", "expect", "project",  "forecast", "intend", "plan", "believe", "project", "potential", and similar  expressions with any discussion of future operating or financial performance  or events. In particular, factors that could cause actual results to differ  materially from those in forward looking statements include the following:  Pivotal's inability to obtain additional financing on acceptable terms; growth  in costs and expenses; inability to compete with others who provide comparable  products; risk that the Company's products will not gain widespread market  acceptance; risks relating to the Company's ability to maintain its CSE  listing. Forward-looking statements speak only as of the date made and are not  guarantees of future performance. The Company undertakes no obligation to  publicly update or revise any forward-looking statements contained in this  document as a result of new information or future events or developments. CSE  has not reviewed and does not accept responsibility for the adequacy or  accuracy of this information.    SOURCE  Pivotal Therapeutics Inc.  Company Contacts:  Rachelle MacSweeney President and Chief Operating Officer Phone:  905-856-9797 E-Mail:rmacsweeney@pivotaltherapeutics.us  Kristine DiMatteo Communications and Public Relations Manager Phone:  905-856-9797 ext. 231 E-Mail:kdimatteo@pivotaltherapeutics.us  www.pivotaltherapeutics.us  To view this news release in HTML formatting, please use the following URL:  http://www.newswire.ca/en/releases/archive/March2014/10/c4208.html  CO: Pivotal Therapeutics Inc. ST: Ontario NI: MTC NASDAQ 2575 WNEWS  
Press spacebar to pause and continue. Press esc to stop.